Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia.
Quignon
F
F
CNRS UPR 9051, Hopital St Louis 1, Paris, France.
Chen
Z
Z
de Thé
H
H
D000818:Animals; D001151:Arsenic; D019677:Artificial Gene Fusion; D002471:Cell Transformation, Neoplastic; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000503:physiopathology / Q000628:therapy*; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D018168:Receptors, Retinoic Acid / Q000502:physiology*; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors / Q000502:physiology*; D014178:Translocation, Genetic; D014212:Tretinoin / Q000502:physiology*; D025521:Tumor Suppressor Proteins
D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human; D014212:Tretinoin; D001151:Arsenic